Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

Bibliographic Details
Main Authors: Fioretto, Paola, Stefansson, Bergur V., Johnsson, Eva, Cain, Valerie A., Sjöström, C. David
Format: Online
Language:English
Published: Springer Berlin Heidelberg 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969341/
id pubmed-4969341
recordtype oai_dc
spelling pubmed-49693412016-08-17 Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment Fioretto, Paola Stefansson, Bergur V. Johnsson, Eva Cain, Valerie A. Sjöström, C. David Research Letter Springer Berlin Heidelberg 2016-06-15 2016 /pmc/articles/PMC4969341/ /pubmed/27306615 http://dx.doi.org/10.1007/s00125-016-4017-1 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Fioretto, Paola
Stefansson, Bergur V.
Johnsson, Eva
Cain, Valerie A.
Sjöström, C. David
spellingShingle Fioretto, Paola
Stefansson, Bergur V.
Johnsson, Eva
Cain, Valerie A.
Sjöström, C. David
Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
author_facet Fioretto, Paola
Stefansson, Bergur V.
Johnsson, Eva
Cain, Valerie A.
Sjöström, C. David
author_sort Fioretto, Paola
title Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
title_short Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
title_full Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
title_fullStr Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
title_full_unstemmed Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
title_sort dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
description
publisher Springer Berlin Heidelberg
publishDate 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969341/
_version_ 1613619088471359488